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creativecommons.org/licenses/by-nc-nd/Abstract Over the past decade, our understanding of cancer immunotherapy has evolved
from assessing peripheral responses in the blood to monitoring changes in the tumour micro-
environment. Both preclinical and clinical experience has taught us that modulation of the
tumour microenvironment has significant implications to generating robust antitumour immu-
nity. Clinical benefit has been well documented to correlate with a tumour microenvironment
that contains a dense infiltration of CD8þCD45ROþ T effectors and a high ratio of CD8þ T
cells to FoxP3þ regulatory T cells (Tregs). In preclinical tumour models, modulation of the
Glucocorticoid induced TNF receptor (GITR)/GITR ligand (GITRL) axis suggests this
pathway may provide the desired biological outcome of inhibiting Treg function while acti-
vating CD8þ T effector cells. This review will focus on the scientific rationale and consider-
ations for the therapeutic targeting of GITR for cancer immunotherapy and will discuss
possible combination strategies to enhance clinical benefit.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).itute for Biomedical Research,
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The goal of anticancer immunotherapy is to re-establish
and enhance the antitumour immune response without
causing concomitant autoimmunity that may itself result
in significant morbidity. In some cases, it is sufficient to
block immunomodulatory molecules responsible for
downregulating inflammation, such as programmed cellan open access article under the CC BY-NC-ND license (http://
D.A. Knee et al. / European Journal of Cancer 67 (2016) 1e102death-1 (PD-1) or programmed cell death-ligand (PD-
L1). Other agents may also allow establishment of an
immune response in a setting where previously there was
little or no evidence of an ongoing antitumour response
such as anti-cytotoxic T-lymphocyte-associated protein
4 (anti-CTLA-4). Despite very promising clinical results,
many patients still do not respond to anti-PD-1/PD-L1,
anti-CTLA4 blockade or combinations of these agents,
substantiating the need for alternative therapeutic stra-
tegies to boost antitumour immunity and improve the
objective response rate in patients with advanced cancer.
One such strategy is targeting GITR, a costimulatory
TNF receptor super family member, which affords the
potential to expand CD8þ T effector (Teff) memory cell
population while promoting the loss or inhibition of
Tregs. In this review, we will discuss the scientific and
therapeutic rationales for targeting the costimulatory
and Treg inhibitory roles of GITR, as a single and
combination agent.2. GITR and GITRL expression
GITR (TNFRSF18/CD357/AITR) is a cell surface re-
ceptor constitutively expressed at high levels on Tregs
and at low levels on naı¨ve and memory T cells [1e3].
Activation of T cells by a number of different stimuli
rapidly increases GITR expression within 24 h, on both
Tregs and Teff cells [1,4]. In mature Tregs, FoxP3 pro-
motes high-level GITR expression [5], while in conven-
tional T cells, canonical NFkB signalling induces GITR
expression [6], suggesting a cell type-intrinsic regulation
of expression. Low to moderate levels of GITR are also
detected on innate immune cells following activation
[1,2,7]. Within innate cell types, the highest induction is
seen on activated natural killer cells with levels compa-
rable to GITR expression on activated Teff cells. Only
intermediate levels are seen on activated macrophage
and dendritic cells (DCs) [8]. Of all immune subsets
studied, activated Tregs exhibit the highest level of
GITR, an important distinction that becomes more
apparent during the in vivo evaluation of GITR
modulation.
Its ligand, GITRL (TNFSF18) is also a member of
the TNF superfamily and is predominantly expressed by
activated antigen presenting cells (APCs), including
DCs, macrophage and activated B cells [4,7]. Notably,
GITR and GITRL expression are not restricted to
haematopoietic cells. For example, GITR has been re-
ported to be expressed at intermediate levels on
epidermal keratinocytes and osteoclast precursors,
whereas GITRL has been detected at high levels on
endothelial cells, particularly following exposure to type
I IFN [2]. Given the expression patterns, the GITR/
GITRL axis may play a role not only in regulating im-
mune responses but also in mediating leukocyte adhe-
sion and migration.3. GITR signalling and function
As a member of the TNFR superfamily, GITR repre-
sents a class of targets referred to as costimulatory re-
ceptors which includes OX40 and 4-1BB (CD137)
among others. GITR signalling and function are context
and cell type dependent (in depth review by Clouthier
and Watts [8]). In the thymus, GITR is expressed during
T cell development and plays a crucial role in thymic
Treg differentiation and expansion [9]. In the periphery,
engagement of GITR on T cells with agonist antibodies,
recombinant GITRL or GITRL transfectants, following
suboptimal TCR stimulation, enhances T cell activation
by upregulating CD25, inducing IL-2 and IFNg
expression, and augmenting proliferation [10e14].
GITR signalling is mediated through the activation of
NFkB and members of the MAPK pathway, including
ERK, p38 and JNK (reviewed in Snell et al. [15]).
AsGITRdoes not have intrinsic enzymatic activity, the
activation of these signalling pathways occurs via
recruitment of TRAF family members, most notably
TRAF2 and TRAF5 [16,17]. TRAF2/5-dependent NFkB
induction following GITR engagement is associated with
upregulation of Bcl-xL expression on activated CD8
þ T
cells, suggesting a potential role for GITR in enhancing
cell survival [16]. Several additional lines of evidence
suggest a unique role for GITR on CD8þ T cells. For
example, GITR signalling lowers the threshold for CD28
signalling on CD8þ T cells [14], induces expression of 4-
1BB in CD8þ memory T cells [18] and promotes survival
of bone marrow CD8þ memory T cells [19]. More
recently, Kim et al. [20] described GITR costimulation
that led to TRAF6-dependent NFkB activation and IL-9
production, thereby enhancing the function of DCs and
promoting cytotoxic T lymphocyte responses. Together,
these data establish the strong costimulatory role for
GITR on Teff cells. However, the regulation of differen-
tial TRAF recruitment and downstream signalling events
is not well understood.
While high GITR expression is clearly a marker for
Tregs [21], its function on Tregs is more complex [21,22].
In general, GITR modulation induces Treg expansion
[23], inhibits Treg suppressive function [11,13,24] and
promotes Teff resistance to Treg suppression
[1,12,25e27]. In addition, GITR is frequently found on
memory or antigen-experienced Tregs, including CD25þ
and CD25e Tregs. In support of this, Bianchini et al.
[28] describe a distinct population of human Tregs
which are CD4þCD25low/eGITRþ and also
CD127highCD45ROþ. The suppressive function of these
cells could be inhibited by treatment with a GITR
agonist antibody, supporting the translational aspect of
GITR modulation from mouse to human while also
highlighting the need to look beyond the traditional
Treg markers when interrogating the pharmacody-
namics of GITR modulation.
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to humanGITR is revealed by the structures of themouse
and human ligand. Classical TNFR ligands are trimeric in
nature and as such, mediate cross-linking of the receptors
which is critical for forward signalling through the
receptor [29e31]. Whereas human GITRL shows the
predicted trimeric structure [32], crystallisation of murine
GITRL led to the identification of a dimeric molecule in
two independent studies [33,34]. This raises the question of
whether or not amultivalentmolecule (trimeric or greater)
is needed to achieve effective human GITR oligomerisa-
tion and costimulatory function.4. In vivo modulation of GITR in preclinical tumour
models
In syngeneic mouse tumour models, GITR modulation
shows compelling antitumour activity which is attrib-
uted to both its costimulatory role on CD4þ and CD8þ
T cells [20,25,35e40] as well as inhibition or depletion of
intratumoural Tregs [20,38,39,41,42]. Table 1 summa-
rises the use of different GITR-targeting agents in pre-
clinical tumour models and the intratumoural effects
observed that relate to the mechanism of action for the
given agent. The most widely used agonist antibody is
DTA-1 which is a rat IgG2b generated by the immuni-
sation of rats with a CD4þCD25þ mouse T cell line [1],
while other antibodies to GITR and versions of re-
combinant GITRL provide additional target validation.4.1. Costimulatory function of GITR modulation
The costimulatory function of GITR has been eluci-
dated in several studies in which DTA-1 or GITRL-Fc
clearly mediates CD8þ T cell expansion and cytokine
production in vivo [25,37,38,40,42]. DTA-1 further en-
hances the multifunctionality of CD8þ T cells in an
adoptive T cell therapy model [43] and can augment
humoural responses in a vaccine model [44]. A recent
study also shows a crucial role for IL-9 in DTA-1-
mediated rejection of CT26 tumours via the induction of
Th9 cells [20]. Furthermore, there is a growing body of
data indicating that GITR modulation enhances the
Teff to Treg ratio, in part through its costimulatory role
of enhancing the CD8þ T cell population, but also
through its depletion of Tregs [20,38,41,42].
Interestingly, multivalent entities of anti-GITR (IgM
molecule [45]) and GITRL (pentameric GITRL [46])
demonstrate agonistic activity in vitro, and while they
show in vivo antitumour activity, tumour regression is
dependent upon in vivo depletion of CD4 cells, presum-
ably due to the loss of CD4þTregs. In fact, pGITRL only
had a transient effect on tumour growth, likely due to the
extensive proliferation of Tregs and lack of FcgR
engagement which is discussed below. Although little
data are available for human cells, Stone et al. [47,48]report that a multimeric macaque GITRL (four-trimer)
augments anti-CD3 and antigen-induced proliferation of
human T cells increases cytokine production and reverses
immunosuppression of Tregs in vitro.
Another antibody that has been utilised in vivo is the
rat monoclonal 2F8 which was shown to induce a
humoural response in a prime boost model and also to
delay the growth of a B16 melanoma tumour [49].
Interestingly, a F (ab0)2 version of 2F8 was as effective
as the intact antibody in enhancing the humoural
response, indicating the Fc is not required [50]. Whether
this is a unique feature of 2F8 or GITR biology regu-
lating a humoural response as opposed to antitumour
immunity remains to be determined.
4.2. Treg function of GITR modulation
The effect of GITR modulation on Tregs in vivo has been
challenging to elucidate as effects have largely not been
observed in the periphery, requiring deeper characterisa-
tion of the tumourmicroenvironment. Several hypotheses
regarding GITR activity on Tregs have been put forward
which are not mutually exclusive including FoxP3 desta-
bilisation [42,51], Treg depletion [38,41,42], inhibition of
Treg suppression (refs) and resistance of Teff cells to
immunosuppression [12,35]. Cohen et al. [42] studied
FoxP3-GFPmice bearing B16 tumours and demonstrated
that DTA-1 treatment resulted in the loss of FoxP3
expression within the intratumoural Treg compartment.
Recent data show that in vitro stimulation of CD4þT cells
with DTA-1 results in activation of the canonical (p50/
RelA) NFkB pathway. Moreover, p50 was shown to
mediate site-specific histone de-acetylation and closure of
the FoxP3 locus [39]. These data correlate with in vivo
observations showing that in a melanoma tumour model
treated with DTA-1, there was a reduction in FoxP3
transcripts and FoxP3þ T cells in lung infiltrates [51].
4.3. Significance of Fc effector function
An important consideration when designing agonistic
antibodies to TNFRSF proteins is that the Fc of the
antibody can interact with both activating and inhibitory
Fcg receptors which may have different outcomes.
Engagement of agonistic antibodies targeting CD40,
DR4 andDR5with the inhibitory FcgR,which promotes
superclustering of the target, is sufficient to enable in vivo
efficacy [30,31]. In contrast, antibody binding to the
activating FcgRcan result in the stimulation of antibody-
dependent cell-mediated clearing of target cells. This
process can either involve NK cells, which mediate anti-
body-dependent cellular cytotoxicity (ADCC), or mac-
rophages, which mediate antibody-dependent cellular
phagocytosis (ADCP). The use of specific FcgR-deficient
mice and chimeric versions of DTA-1, which are not
capable of binding to any FcgR, demonstrated that
activating FcgRs are required for the ability of DTA-1 to
Table 1
In vivo evaluation of GITR-targeting agents.
GITR agonist Description Models Intratumoural changes Reference
DTA-1 Rat IgG2b MethA  Eradication of established tumours
 Increase infiltration of CD4þ and CD8þ T
cells
 Response was not seen in IFNg deficient
mice
Ko et al. 2005, J Exp Med
DTA-1 Rat IgG2b MB49  Eradication of established tumours
 Increase infiltration of CD4þ and CD8þ T
cells
 Decrease in CD4þFoxP3þ Tregs
Coe et al. 2010, Canc Imm Immunother
DTA-1 Rat IgG2b B16  Delay in tumour cell growth
 Rejection requires CD4þ, CD8þ, and
NK1.1þ cells
 Rejection is dependent on IFNg and FasL
and independent of perforin
Ramirez-Montagut et al. 2006, J Imm
DTA-1 Rat IgG2b B16  Inhibition of tumour growth
 Decrease of FoxP3þ Tregs
 Increase in CD8þCD44hiCD62Llo cells
 Increase in CD8þ IFNgþ cells and CD8þ
proliferating cells
Cohen et al. 2010, PLoS One
DTA-1 Rat IgG2b B16  Inhibition of tumour growth and induction
of concomitant immunity
 Enhancement of tumour-specific CD8þ
CTL
 Depletion of CD8þ T cells impairs second-
ary challenge with same tumour
Cote et al. 2011, J Imm
DTA-1 Rat IgG2b B16  Conversion of Treg to Teff cell phenotype
(loss of FoxP3, Helios and IL-10 expression
but increase in IFNg and Eomes in DTA-1
treated Tregs)
Schaer et al. 2013, Canc Imm Res
DTA-1 Rat IgG2b B16-OVA  Reduction in number of tumour foci in the
lung
 Decrease in FoxP3þ Tregs
 Increase in CD4þ IL9þ (Th9) cells
Xiao et al. 2015, Nat Comm
DTA-1 Rat IgG2b B16F10-OVA  Decrease in FoxP3þ Tregs
 Increase in CD8þ/Treg ratio
Kim IK et al. 2015, Nat Med
DTA-1 Rat IgG2b CT26  Tumour regression is dependent upon
GITR-induced Th9 cells
 Increase in tumour-specific CD8þ CTLs via
IL9 activation of tumour-infiltrating DCs
Kim IK et al. 2015, Nat Med
DTA-1 Rat IgG2b CT26  Tumour rejection is dependent on CD4þ
effector T cells
 CD4þ T cells play a central role in orches-
trating multiple effector cells of anti-GITR
mAb-induced tumour rejection, including
CD8þ T cells and NK cells
Zhou et al. 2007, J Imm
DTA-1 Mouse IgG2a Colon26  Eradication of established tumours
 Depletion of CD4þFoxP3þ Tregs, depen-
dent on activating FcgR
 Increase in CD8þ/Treg ratio
Bulliard et al. 2013, J Exp Med
DTA-1 N297A Mouse
IgG2a-
N297A
Colon26  No regression of tumours
 No depletion of Tregs
Bulliard et al. 2013, J Exp Med
G3c Rat IgM Colon26  No effect on tumour growth
 Increased number of Tregs
Nishioka et al. 2008, Imm Letters
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Table 1 (continued )
GITR agonist Description Models Intratumoural changes Reference
mGITRL Fc Dimeric
mouse
GITRL
(Fc isotype
unknown)
Colon26 RENCA  Tumour regression in both models
 Increased TILs and Granzyme B with Fc-
mGITRL and DTA-1
 Increase in CD11bþ macrophage with Fc-
mGITRL
 Depletion of CD8þ T cells significantly
reduced the effect of Fc-mGITRL
Hu et al. 2008, Clin Canc Res
pGITRL Pentameric
mouse
GITRL (no
Fc)
MC38  Delayed tumour growth
 Depletion of CD4þ T cells led to complete
regression with pGITRL
 Combination of CD4 depletion and
pGITRL led to loss of Tregs and increased
CD8þ T cells
Kim YH et al. 2015, J Imm
mGITRL Plasmids
encoding
mouse
GITRL
CMS5  Delay in tumour growth
 Depletion of CD8þ T cells abolished effect
of GITRL
Nishikawa et al. 2008, Cancer Res
NK, natural killer; TIL, tumour infiltrating lymphocyte.
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the tumour infiltrating lymphocytes (TILs) showed that
Tregs were rapidly depleted in the tumour microenvi-
ronment but not in the periphery. The level of antigen
expression contributes to the efficiency of ADCC [53],
and indeed, intratumoural Tregs have the highest level of
GITR expression compared to both peripheral Tregs and
activated Teff cells [38,41,42]. Antibody/FcgR-mediated
loss of Tregs within the tumour microenvironment is
observed for several other targets expressed at high level
on intratumoural Tregs including CTLA4 [41,54,55] and
OX40 [56].
4.4. Preclinical combination of anti-GITR with other
treatment modalities
While GITR modulation demonstrates promising anti-
tumour activity in a variety of preclinical models, the
most robust activity is seen with smaller tumours which
are more sensitive to immunotherapy in general and
may be less likely to predict results in the clinical setting.
For larger established tumours, combination strategies
using mechanistically different therapies are being
investigated. Blocking the PD-1/PD-L1 axis to over-
come T cell exhaustion provides an opportunity to
enhance anti-GITR therapy. Indeed, anti-PD-1 plus
anti-GITR therapy in an ovarian model (1D8) led to
increased overall survival with 20% of mice tumour free
90 days following treatment [57]. TILs from the
responding mice demonstrated a dramatic increase in
CD4þ and CD8þ effector memory (CD44þCD26Le) T
cells with a concomitant decrease in CD4þFoxP3þ Tregs
and myeloid-derived suppressor cells. Triple combina-
tion of cisplatin or paclitaxel with anti-PD-1 and anti-
GITR further improved response to >80% of mice
that were tumour free at day 90, in both the ovarian anda breast cancer model. The dramatic improvement in
response with the triple combination highlights the po-
tential benefit for more complex combination strategies
in the clinic that target different mechanisms.
Another strategy is to promote T cell priming and
infiltration through the combination of anti-GITR with
anti-CTLA4 treatment. Using MethA and CT26 tumour
models under conditions where monotherapy was inef-
fective, anti-GITR and anti-CTLA4 combination
demonstrated robust, synergistic antitumour activity
[25,27]. Mechanistic evaluation indicated that anti-
CTLA4 treatment enhanced the proliferation and infil-
tration of CD8þ Teff cells into the tumour, while anti-
GITR treatment reduced the accumulation of intra-
tumoural Tregs [26,27]. The combination thus led to a
higher frequency of proliferating CD8þ Teff cells pro-
ducing greater quantities of IFNg. Translating these
findings to the human setting, Pedroza-Gonzalez et al. [58]
reported that intratumoural Tregs from hepatic cellular
carcinoma or liver metastases from colorectal cancer pa-
tient samples express high levels of bothGITRandCTLA-
4. Ex vivo stimulation of the TILs with a combination of
low-dose solubleGITRL and anti-CTLA-4 restored T cell
function by a largely additive effect on proliferation and
TNFa production compared to either monotherapy.
Tumours exhibiting low antigen-burden may require
T cell priming prior to or in conjunction with anti-GITR
therapy. Using intratumoural delivery of adenovirus
expressing interferon alpha (IFNa), coadministration of
anti-GITR intraperitoneally enhanced antitumour ac-
tivity and led to an abscopal effect [59]. The combina-
tion strategy synergistically increased the number of Teff
cells in the tumour while reducing the number of Tregs,
in part due to a potentially novel mechanism of CCR5
downregulation. In a unique cellular therapy, DCs were
engineered to secrete either GITRL-Fc or GITR Ab and
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the two DC populations into the same site led to dra-
matic antitumour activity and prolonged survival [60]. A
follow-on study in which human DCs coexpressed
human GITRL-Fc (hIgG1) and anti-human CTLA-4
heavy and light chains demonstrated enhanced induc-
tion of tumour antigen-specific CTLs [61] which led to
the initiation of a phase I vaccine study in metastatic
melanoma. As another approach to cell therapy com-
binations with GITR agents, adoptive T cell therapy
models demonstrate that DTA-1 enhances the multi-
functionality of CD8þ T cells (cytokine production and
proliferation) while also reducing the number of FoxP3þ
Tregs, leading to improved overall survival [43,62].5. Clinical testing of anti-GITR biologics
5.1. Considerations for indication selection
A growing number of clinical studies document the
favourable prognostic importance of a CD8þCD45ROþ
memory cell infiltrate in a variety of cancer types [63,64].
Based on preclinical data, the emerging hypothesis is
that a GITR agonist antibody with the ability to bind
activating FcgR should shift the balance in the CD8þ
Teff/Treg ratio to impart robust antitumour immunity.
The clinical utility of anti-GITR antibodies as single
agents may vary depending upon the pretreatment bal-
ance of Tregs to Teffs, the presence of NK cells and
macrophages capable of ADCC or ADCP, respectively,
as well as the subsets of Tregs present in the tumour.
Selection of tumour types most likely to benefit from
treatment with agents targeting Tregs, including anti-
GITR antibodies, may be guided by data suggesting that
functional Tregs are a component of the TIL population
[21]. In an early study by Curiel et al. [65], Tregs derived
from ascites of ovarian patients were shown to be
CD4þCD25þGITRþCTLA4þFOXP3hi, functionally
suppressive and associated with a high risk of mortality.
Since that publication, numerous reports have described
the association of tumour infiltrating Tregs with poor
prognosis in a variety of indications including hepato-
cellular (HCC), lung, renal cell carcinoma, cervical, and
melanoma [63,66]. Thymus-derived Tregs
(CD4þFoxP3þHeliosþ) which are most prominent in
glioblastoma are GITRþ [67]. Furthermore, Tregs found
within HCC tumours and in metastatic colorectal cancer
sites have a higher surface expression of GITR than
circulating Tregs, suggesting that strategies directed at
elimination of Tregs may have a preferential effect within
the tumour microenvironment [68], provided innate im-
mune cells expressing activating FcgR are also present.
However, data from colorectal, breast, head and neck,
lymphoma and even ovarian have reported both positive
and negative prognostic outcomes associated with intra-
tumoural Tregs [63,66]. In depth evaluation of thesereports indicates several factors may contribute to these
seemingly disparate findings including methodologies for
identifying Tregs and the site of the tumour [69]. Of 58
studies evaluated, 50 used FoxP3 as a sole identifier for
Tregs. The challenge with this is approach is that human
Teff cells can transiently express FoxP3 upon activation
[70,71]. The inclusion of other markers such CD4, CD8,
CD25 and CCR4 alongside FoxP3 has provided better
prognostic associations. Utilizing advanced technologies
that incorporate evaluation of GITR expression to assess
Treg and Teff composition pre- and post-treatment might
provide better mechanistic insight into GITRmodulation
and potential patient stratification.
The tumour type and role of disease-causing inflam-
mation may also be relevant to the prognostic impor-
tance of Tregs. In colorectal cancer, Tregs are thought
to control a Th17-mediated pro-inflammatory response
that supports tumour growth suggesting a favourable
role in this setting [72]. Similarly, high Treg content in
stromal TILs associated with gastric cancer of the cardia
appears to result in prolonged disease-free survival [73].
Based on these findings, careful consideration should be
given to the indication before employing the use of Treg-
targeting agents.
5.2. Potential for toxicity
The immune-related adverse events (IRAEs) observed
with checkpoint inhibitors (anti-PD-1, PD-L1 and
CTLA-4) are similar, but combination treatment may
increase both the frequency and severity of adverse events
(AEs). The overall incidence of treatment-related grade 3/
4 AEs with CTLA-4 and PD-1 blockade monotherapy is
27% and 16%, respectively. In combination, ipilimumab
and pembrolizumab enhanced toxicity causing a 55% rate
of high-grade AEs [74]. Similarly, due to the elimination
of Tregs, agents targeting GITR may increase the fre-
quency of IRAEs. Preclinical differences in CTLA-4- and
GITR-mediated toxicity support the possibility that
strategies targeting GITR will be better tolerated than
CTLA-4 blockade. CTLA-4 knockout mice have a fatal,
early-onset defect in T cell tolerance impacting both
conventional T cells as well as Tregs [75]. In contrast,
GITR-null mice develop normal lymphoid organs and do
not develop overt autoimmunity [1,76].While DTA-1 can
exacerbate pre-existing inflammation and autoimmune
disease [1,2], the use of DTA-1 in tumour models has not
led to autoimmunity across a number of models and
mouse strains [25,27,60] except for very mild hypo-
pigmentation during melanoma therapy [36,42].
5.3. Therapeutic agents in development and ongoing
clinical trials
A number of agents have entered the clinic or will do so
in the near future (Table 2). These include traditional
bivalent antibodies and multivalent GITR ligand fusion
Table 2
Clinical trials with GITR-targeting agents.
Drug Indication Phase
(start
date)
NCT number
TRX518 (GITR, Inc.)
Aglycosyl human IgG1
Melanoma
(lead)
Solid
tumours
Phase I
(10/2010)
Phase I
(12/2015)
NCT01239134
NCT02628574
MK-4166 (Merck)
(pembrolizumab)
Solid
tumours
Phase I
(06/2014)
NCT02132754
MK-1248 (Merck)
(pembrolizumab)
Solid
tumours
Phase I
(11/2015)
NCT02553499
AMG 228 (Amgen) Solid
tumours
Phase I
(04/2015)
NCT02437916
BMS-986156 (BMS)
(nivolumab)
Solid
tumours
Phase I
(10/2015)
NCT02598960
INCAGN01876
(Incyte/Agenus)
Human IgG1
Solid
tumours
Phase I/II
(06/2016)
NCT02697591
MEDI1873 (AZ)
Hexameric
GITRL protein
Human IgG1
Solid
tumours
Phase I
(11/2015)
NCT02583165
GWN323 (NVS)
(PDR001)
Human IgG1
Solid
tumours
Phase I/Ib
(07/2016)
NCT02740270
FcR
GITR GIT
CD
NK cell
Induce
depletion
Treg cell
Multivalent
GITRL
αGITR
Immuno-suppression
Treg cell
Fig. 1. Model for GITR modulation of antitumour immunity. In th
antibodies that can also bind to activating FcgR on NK cells (or mac
due, in large part, to the fact that activated Tregs express the highest
shown in the right portion of the figure, is mediated by oligomerisation
by treatment with soluble, multivalent GITRL or with agonist antibo
activating FcgRþ immune cells. The downstream signalling followin
functions, depending on the targeted cell type. The combination of re
timulatory function of CD8þ Teff cells leads to improved antitumour
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valence are likely to impact the balance of Treg deple-
tion and Teff stimulation. TRX518, a humanised non-
depleting antibody, was the first antibody to enter the
clinic in 2010 for malignant melanoma. The first study
was a single-ascending dose escalation showing little
toxicity or efficacy. A new dose escalation study with
repeat-dosing opened in December 2015. In contrast,
INCAGN01876 and GWN323, both human IgG1, are
capable of engaging Fcg receptors and have demon-
strated ADCC competency in vitro ([77]; unpublished
data). At least four other anti-GITR antibodies are in
development although limited information is available
with respect to isotype and effector function. A novel
agent, MEDI1873, is a hexameric GITRL molecule with
a human IgG1 Fc domain [78]. This design may provide
an opportunity to maximise multimerisation of GITR
and its costimulatory function on Teff cells while
depleting or inhibiting Tregs. A phase I trial in select
advanced solid tumours is currently open.
Agonists against other TNFR family members have
faced some hurdles in the clinic with respect to toxicity (4-
1BB)orminimal early efficacy (OX40).However, increased
understanding of target biology in preclinical models andFcR
FcR
R
GITR
8+ Teff  cell
αGITR
Anti-tumour immunity
Innate-immune
accessory cell
↑ Proliferation
↑ Cytokine production
↑ CD8+ memory T cells
↑ Induce CD4+ Th9 cells
CD8+ Teff cell
e tumour microenvironment, engagement of GITR on Tregs by
rophage) leads to Treg depletion. The biased depletion of Tregs is
level of GITR. The costimulatory function of GITR modulation,
of GITR on Teff cells. Clustering of GITR can be induced either
dy/FcR mediated cross-linking via coengagement of inhibitory or
g GITR multimerisation can lead to a variety of costimulatory
duced immunosuppression via Treg depletion and enhanced cos-
immunity. NK, natural killer.
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reinvigorated efforts for both OX40 [79] and 4-1BB [80].
Interestingly, while GITR, OX40 and 4-1BB share simi-
larities in their expression patterns and downstream sig-
nalling pathways, they also exhibit unique characteristics,
suggesting they are not redundant molecules.
Based on the clinical experience with antibodies tar-
geting CTLA-4 and the PD-1/PD-L1 axis along with the
preclinical data for GITR, the expectation is that GITR-
targeting therapies will require combination strategies
with other immunomodulatory agents to overcome the
immunosuppressive tumour microenvironment of solid
tumours. As is shown in Table 2, several companies are
already designing combination strategies of anti-GITR
with anti-PD-1 agents.
6. Conclusions and future perspectives
Deeper mechanistic understanding of GITR-targeting
agents in preclinical models reveals a previously under-
appreciated role of the Fc effector function to promote
Treg depletion while further highlighting the importance
of GITR oligomerisation to achieve downstream cos-
timulatory signals (Fig. 1). With currently eight different
molecules registered in ClinicalTrials.gov and employing
different modalities, the translational relevance of tar-
geting GITR in human tumours can now be evaluated.
Furthermore, the ability of GITR modulation to
enhance the CD8/Treg ratio via two seemingly disparate
mechanisms (Treg depletion and costimulation of Teff
cells) provides a novel combination partner with check-
point inhibitors to increase the response rate and duration
of response. Recognizing that the immune system is dy-
namic, the success of any of these agents, especially as
combination partners, will depend heavily on the inter-
rogation of the tumour microenvironment and pharma-
codynamics of these agents. Long-termdepletion ofTregs
or sustained blockade of checkpoint inhibitors may be
counterproductive to achieving the right balance of im-
mune stimulation versus immune suppression. Nonethe-
less, this is an exciting time for the field. With the
explosion of new immunomodulatory agents in the clinic
and sophisticated technologies to enable better immune
monitoring within the tumour, we have the opportunity
to significantly advance the regulation of tumour immu-
nity and hopefully, transform the lives of cancer patients.
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